STA551

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

CD137 agonist

Related drugs:

‹

›

16d

Quantitative Investigation of ATP Switch Concept of STA551 Through Combined In Vivo Tissue Distribution Studies and Physiologically Based Pharmacokinetic Modeling. (PubMed, AAPS J)

In conclusion, this combination approach successfully demonstrated the ATP switch concept of STA551 in vivo. These findings will help guide clinical trials for STA551 and the development of future switch antibodies.

16 days ago

PK/PD data • Preclinical • Journal

TNFRSF9 (TNF Receptor Superfamily Member 9)

STA551

3ms

STA101JG: A Phase I study of STA551 and STA551 in combination with atezolizumab in patients with solid tumours (2023-508764-30-00)

P1, N=30, Active, not recruiting, Chugai Pharmaceutical Co. Ltd. | -> Active, not recruiting | Phase classification: PN/A --> P1

3 months ago

Enrollment closed • Phase classification

Tecentriq (atezolizumab) • STA551

4years

Single cell RNA sequencing revealed that the mechanism of the synergistic efficacy of STA551 and immune checkpoint inhibitor results from the induction of highly activated T cells in tumor (AACR 2022)

The combination of STA551 and PD-L1 showed synergistic anti-tumor efficacy in a colon38-bearing human CD137 knock-in mouse model. Detailed mechanistic analysis showed that the combination of STA551 and PD-L1 induced highly activated CD8+T cells expressing chemokines and cytokines compared to monotherapy. This cluster also express chemokines, suggesting that other immune cells have been recruited.

4 years ago

Clinical • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8)

PD-L1 expression

STA551